Organization
Amsterdam University Medical Centers
8 abstracts
Abstract
ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).Org: Sarah Cannon Research Institute/Tennessee Oncology, Jilin Cancer Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Federal State Budgetary Institution “N. N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Beijing Cancer Hospital,
Abstract
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.Org: Melanoma Institute Australia, The Netherlands Cancer Institute, Amsterdam University Medical Centers, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The Christie NHS Foundation Trust,
Abstract
The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.Org: Leiden University Medical Center, Institut de Cancérologie Gustave Roussy, London Regional Cancer Program Ontario, Tübingen University Hospital, Fondazione Policlinico Universitario A. Gemelli IRCCS,
Abstract
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).Org: University Medical Center Utrecht, Utrecht University, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus Medical Center, Amsterdam University Medical Centers,
Abstract
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.Org: Division of Surgical Oncology, Department of Surgery, The Ohio State University, Netherlands Cancer Institute, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, The Netherlands Cancer Institute,
Abstract
‘SCIENTIFIC DATA VISUALIZATION: FOCUS ON (POSTER) PRESENTATIONOrg: Amsterdam University Medical Centers, Vrije Universiteit Brussel, Epidemiology and Biostatistics, Amsterdam Rheumatology and immunology Center,
Abstract
ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRE-CLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIALOrg: King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, University of Birmingham, Sandwell and West Birmingham NHS Trust, Catholic University of the Sacred Heart, Rome, Italy,
Abstract
BELIMUMAB INCREASES SRI-4 RESPONSE RATES VERSUS PLACEBO IN EARLY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A LARGE INTEGRATED ANALYSIS OF BELIMUMAB TRIALSOrg: GSK Research and Development Upper Providence, Collegeville, PA, Brigham and Women’s Hospital, Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology, Oklahoma City, United States of America, Rheumatology unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, Hokkaido University Hospital Cancer Center,